A cohort study assessing a blood test for early cancer detection in Nanjing

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Jinling Cohort is a prospective, multicenter observational study involving 15,000 individuals aged 45-75 in Nanjing, China. Participants will undergo blood collection for the MERCURY multi-omics liquid biopsy test, complete health questionnaires, and annual physical exams over three years, followed by two additional years of follow-up. The study aims to evaluate the test's sensitivity, specificity, and predictive values, as well as its ability to detect multiple cancer types earlier than conventional methods. Additionally, it will assess participants' attitudes towards the MCED blood test.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1、45-75 years of age; 2、Willing and able to undergo blood sample collection, health questionnaires and annual routine physical exams once a year for three consecutive years; 3、Residents in Nanjing; 4、Fully understand the study and able to provide a written informed consent

Exclusion Criteria:

1. Pregnant women;
2. Individuals who have history of cancer or current diagnosis of cancer;
3. Individuals who have organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;
4. Individulas who have blood transfusion within 30 days prior to the blood draw;
5. Individuals who have an acute infection or inflammation within 14 days prior to the blood draw;
6. Individuals who have taken medication with anti-tumor effects within 30 days prior to the blood draw;
7. Individuals who will not be able to comply with the protocol procedures judged by researchers

Where it's running

• Nanjing Jiangbei People's Hospital
  Nanjing, Jiangsu, China Recruiting
• The Fourth Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Principal investigator: Shao Yang, Ph.D — NanjingShihejiyin Technology Inc.
• Study coordinator: Shanshan Yang, Ph.D
• Email: admin@geneseeq.com
• Phone: 8613585145836

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood exosomal RNA test to rule out prostate cancer spread to bone

  This project will try a blood-based exosomal RNA test to see if it can rule out bone metastasis in people with newly diagnosed, treatment‑naïve prostate cancer scheduled for baseline PSMA PET.

  Recruiting at 9 sites Xijing Hospital · Lanzhou, Gansu and 8 other locations · NCT07553754

• ctDNA analysis on archived plasma to gauge minimal residual disease in epithelial ovarian cancer

  A single-center study will test whether ctDNA from archived and current blood samples can help identify minimal residual disease in epithelial ovarian cancer patients after surgery.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07546578

• Using urinary tumor DNA to guide how long systemic immunotherapy is given for unresectable very‑high‑risk non‑muscle‑invasive bladder cancer.

  This trial will test whether monitoring urinary tumor DNA lets people with unresectable very‑high‑risk non‑muscle‑invasive bladder cancer stop systemic immunotherapy sooner after they have a complete clinical response.

  Recruiting at 3 sites Phase 2 Tianjin Medical University Second Hospital · Tianjin and 2 other locations · NCT07475403

• Intracranial Venous Blood Sampling for Brain Tumor Liquid Biopsy

  This study tests whether taking blood from veins inside the brain can safely and reliably reveal molecular information about high-grade gliomas using a liquid biopsy.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07467109

• Liquid biopsy testing to identify, monitor, and predict recurrence in urothelial carcinoma

  This project tests whether a multi-component liquid biopsy (blood and urine ctDNA, urine tumor DNA, exosomes, and protein biomarkers) can help detect disease, track treatment response, and predict recurrence in people with suspected or confirmed urothelial carcinoma.

  Recruiting Tianjin Medical University Second Hospital · Tianjin · NCT07441499

• Using urine tumor DNA to guide whether to have a second bladder tumor resection

  This study will test whether a urine tumor DNA (utDNA) test can help decide if adults with T1 or uncertain non‑muscle‑invasive bladder cancer need a second transurethral resection (re‑TURBT).

  Recruiting at 7 sites Tianjin Medical University Second Hospital · Nanchang, Anhui and 6 other locations · NCT07187635

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.